Ophthotech Corp (OPHT) Tops Q3 EPS by 2c

Ophthotech Corp (NASDAQ: OPHT) reported Q3 EPS of ($0.41), $0.02 better than the analyst estimate of ($0.43).

“During 2018 Ophthotech made significant progress in bringing together a diversified pipeline of therapeutic and gene therapy programs for the treatment of retinal diseases,” stated Glenn P. Sblendorio, Chief Executive Officer and President of Ophthotech. “Today, we announced two transactions that add compelling opportunities to our existing pipeline of retinal programs, and through the acquisition of Inception 4, Inc. we are excited to welcome Versant Ventures as a major shareholder of Ophthotech. We are on track to provide topline data from our Zimura program in wet age-related macular degeneration by the end of this year, followed by topline data in geographic atrophy secondary to dry AMD in the second half of 2019 and in Stargardt disease in 2020. We look forward to advancing and expanding our pipeline of age-related and orphan retinal diseases and creating value for our shareholders.”

For earnings history and earnings-related data on Ophthotech Corp (OPHT) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Ecolab pops as Citi sees improving setup into Q2 earnings
• KB Home (KBH) PT Raised to $56 at Truist Securities